In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback